Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

An in vivo patient-derived model of endogenous IDH1-mutant glioma

13 Dec 2011

Abstract excerpt

Somatic mutations in the catalytic domain of isocitrate dehydrogenase (IDH) 1/2 and accumulation of the oncometabolite 2-hydroxyglutarate (2-HG) appear to be among the earliest events in gliomagenesis and may contribute to malignant transformation. The lack of cell lines with endogenous mutations has been one of the major challenges in studying IDH1/2-mutant glioma and developing novel therapeutics for these...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer, Hypoxia, and Metabolism
Share to Glioma Diagnosis and Treatment
Share to Immune cells in cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 22166263
DOI: 10.1093/neuonc/nor207

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

An in vivo patient-derived model of endogenous IDH1-mutant gliomaPMID 22166263Read ↗

Mutant IDH1 Promotes Glioma Formation In VivoSemantic proximity Read ↗

Long-term administration of the mutant IDH inhibitor DS-1001b suppresses the growth of IDH1-mutant glioma in vitro and in mouse xenograft models and alters epigenetic profiles.Semantic proximity Read ↗

A Potent Blood-Brain Barrier-Permeable Mutant IDH1 Inhibitor Suppresses the Growth of Glioblastoma with IDH1 Mutation in a Patient-Derived Orthotopic Xenograft Model.Semantic proximity Read ↗

Molecular biology and novel therapeutics for IDH mutant gliomas: The new era of IDH inhibitors.Semantic proximity Read ↗

Disruption of wild-type IDH1 suppresses D-2-hydroxyglutarate production in IDH1-mutated gliomas.Semantic proximity Read ↗

Current biomarker-associated procedures of cancer modeling-a reference in the context of IDH1 mutant gliomaSemantic proximity Read ↗

Generation of induced neural stem cells with inducible IDH1R132H for analysis of glioma development and drug testing.Semantic proximity Read ↗

A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas.Semantic proximity Read ↗

IDH1 and IDH2 mutations as novel therapeutic targets: current perspectivesSemantic proximity Read ↗

A Brain Penetrant Mutant IDH1 Inhibitor Provides In Vivo Survival Benefit.Semantic proximity Read ↗

A patient-derived cell model for malignant transformation in IDH-mutant glioma.Semantic proximity Read ↗

Autophagy and oxidative stress in gliomas with IDH1 mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.